Company Overview - Equillium, Inc. (EQ) is expected to report a year-over-year increase in earnings, with a projected EPS of 36.35 million, which is an increase of 309.8% compared to the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 11.24% higher in the last 30 days, indicating a positive reassessment by analysts [4] - However, the Most Accurate Estimate for Equillium is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -514.29%, suggesting a bearish outlook from analysts [10] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of an earnings beat, but the predictive power is significant only for positive readings [7][8] - Equillium's current Zacks Rank is 4 (Sell), which complicates the prediction of an earnings beat [10] Historical Performance - In the last reported quarter, Equillium had a surprise of +106.67%, posting earnings of 0.15 [11] - The company has beaten consensus EPS estimates in all of the last four quarters [12] Industry Comparison - Spero Therapeutics, another company in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $0.27 per share, indicating a year-over-year change of -1,450% [16] - Spero Therapeutics has an Earnings ESP of 107.55% and a Zacks Rank of 2 (Buy), suggesting a higher likelihood of beating the consensus EPS estimate [17]
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth